Motaz Daraghma

Dr. Motaz Daraghma

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Polish Journal of Radiology
Verified
Journal Article
Open access
HHHashim Talib Hashim
Hashim Talib Hashim
AAAhmed Qasim Mohammed Alhatemi
Ahmed Qasim Mohammed Alhatemi
MDMotaz Daraghma
Motaz Daraghma
HAHossam Tharwat Ali
Hossam Tharwat Ali
MKMudassir Ahmad Khan
Mudassir Ahmad Khan
AAAhmed Dheyaa Al-obaidi
Ahmed Dheyaa Al-obaidi
Purpose: Early detection of breast cancer is crucial for improving patient outcomes. With advancements in artificial intelligence (AI), there is growing interest in its potential to assist radiologists in interpreting mammograms for early cancer detection. AI algorithms offer the promise of increased accuracy and efficiency in identifying subtle signs of breast cancer, potentially complementing the expertise of radiologists and enhancing the screening process for early-stage breast cancer detection.Material and Methods: A systematic literature review was conducted to identify and select original research reports on breast cancer diagnosis by artificial intelligence versus conventional radiologists in using mammograms in accordance with the PRISMA guidelines. Data were analysed with Review Manager version 5.4. P-value and I2 were used to test the significance of differences.Results: This systematic review and meta-analysis included 8 studies with data from a total of 120,950 patients. Regarding the sensitivity of AI, the pooled analysis of 6 studies with sensitivities ranging from 0.70 to 0.89 yielded a sensitivity of 0.85. However, the sensitivity of the radiologists ranged from 0.63 to 0.85, with an overall sensitivity of 0.77. As for specificity, both radiologists and AI groups had closer results.Conclusions: The comparison between AI systems and radiologists in detecting early-stage breast cancer from mammograms highlights the potential of AI as a valuable tool in breast cancer screening. While AI algorithms have shown promising results in terms of accuracy and efficiency, they should be viewed as complementary to radiologists rather than replacements.

27 April 2023 in Journal of Ethnicity in Substance Abuse
Verified
Journal Article
Closed access
Basma DamiriBasma Damiri
Basma Damiri
MDMotaz Daraghma
Motaz Daraghma
Illicit drug use is bound by a religious, social, and cultural stigma in Palestine. The extent of illicit drug use in Palestine is difficult to estimate due to the limited availability of research and challenged by poor measurement and inconsistent reporting. Concern about the hidden nature of drug use continues to be reported. We investigated the prevalence and risk factors associated with illicit drug use in the north of the West Bank. We compared the results between refugee camps and rural and urban areas. The recruited males (N = 1045) were invited to fill out a self-administrated questionnaire and to give urine samples in 2022. Multi-line drug screen test in urine was used as a screening tool to evaluate the presence of 12-drugs in urine samples. The respondents (N = 656) were aged 15-58 years. At least one drug was detected positive in 19.1% of the participants’ urine samples, with the highest percentages among refugees (25.9%), followed by rural (13.6%) and urban participants (10.9%) (P-value < 0.001). Moreover, around half of the drug users were multidrug users. Refugees were 3.8 times (P-value = 0.002), and urban were 2.3 times (P-value = 0.033) more likely to be drug users than rural participants. Besides the geographical factors, socio-demographic factors like age (<30 years), marital status (single), drinking alcohol, and vape-smoking played significant roles in the increasing risk of illicit drug use in the West Bank. The findings from this study draw attention to our limited understanding of the epidemiology of substance use among Palestinians.

23 January 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
TFTobias Djamsched Faizy
Tobias Djamsched Faizy
VYVivek Yedavalli
Vivek Yedavalli
Hamza A SalimHamza A Salim
Hamza A Salim
DLDhairya A Lakhani
Dhairya A Lakhani
BMBasel Musmar
Basel Musmar
AGAdrien Guenego
Adrien Guenego
Background Current randomized controlled trials are investigating the efficacy and safety of mechanical thrombectomy (MT) in patients with medium vessel occlusion (MeVO) stroke. Whether best medical management (MM) is more efficient than unsuccessful vessel recanalization during MT remains unknown. Methods This was a retrospective cohort study using data from 37 academic centers across North America, Asia, and Europe between September 2017 and July 2021. Only patients with occlusion of the distal branches (M2 and M3) of the middle cerebral artery territory were included. Unsuccessful MT was defined as a modified Thrombolysis in Cerebral Infarction score of 0–2a. Propensity score matching was used to control for confounders. The primary outcome was functional independence, defined as a modified Rankin Scale (mRS) score of 0–2 at 90 days after treatment. Multivariable regression analysis was used to assess factors associated with the primary outcome. Results Of 2903 patients screened for eligibility, 532 patients were analyzed (266 per group) after propensity score matching. The MM group had superior functional outcomes, with 32% achieving mRS 0–1 at 90 days compared with 21% in the MT group (P=0.011). Patients in the MM group also had significantly lower rates of symptomatic intracranial hemorrhage (sICH) (3.4% vs 16%, P<0.001) and any hemorrhage (18% vs 48%, P<0.001). On multivariable regression, unsuccessful MT was associated with reduced odds of functional independence (OR 0.50, 95% CI 0.29 to 0.85, P=0.011) and increased odds of sICH (OR 4.32, 95% CI 1.84 to 10.10, P<0.001). Mortality rates were similar between groups (27% in MM vs 29% in MT, P=0.73). Conclusion Unsuccessful MT for MeVO was linked to worse outcomes than best MM. These findings highlight the risks of prolonged attempts and emphasize the importance of efficient procedural decision-making to reduce complications and improve patient outcomes.

Verified
Journal Article
Open access
PDF file
MDMotaz Daraghma
Motaz Daraghma
MGMichael M. Graham
Michael M. Graham
Radioactive iodine (RAI) therapy plays a fundamental role in the management of differentiated thyroid cancer (DTC) following appropriate surgical intervention. High levels of TSH are required in order to achieve maximum RAI uptake in residual thyroid tissue or metastatic cells. The two techniques that are most commonly used are thyroid hormone withdrawal (THW), which induces endogenous TSH elevation by creating a hypothyroid state, and exogenous stimulation with recombinant human TSH (rhTSH). This review compares both approaches over a range of DTC risk categories. Extensive evidence demonstrates that rhTSH and THW yield equivalent oncological outcomes, including remnant ablation success, recurrence-free survival, and overall survival, in low-, intermediate-, and high-risk disease. Additionally, rhTSH maintains quality of life by avoiding hypothyroid symptoms. While THW continues to be an excellent option when there is a lack of availability of rhTSH, its disadvantages, particularly the transient hypothyroid state, must be carefully weighed against the demonstrated equivalence in efficacy. In current clinical practice, rhTSH is frequently the preferred option for its convenience, safety, and patient-centered benefits; however, the selection of the optimal approach should be based on individual clinical circumstances and patients’ preferences, as well as resource considerations.

5 March 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
Hamza A SalimHamza A Salim
Hamza A Salim
VYVivek Yedavalli
Vivek Yedavalli
DLDhairya A Lakhani
Dhairya A Lakhani
FMFathi Milhem
Fathi Milhem
BMBasel Musmar
Basel Musmar
MIMAD MT Investigators
MAD MT Investigators
Background Mechanical thrombectomy (MT) is established as an effective treatment for large vessel occlusion strokes, but its efficacy and safety for medium vessel occlusions (MeVOs) remain less clear. This study examines the impact of periprocedural embolization to a new vascular territory (ENT) on clinical outcomes in patients with MeVO stroke treated with MT. Methods A multicenter, retrospective analysis was conducted using the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry, including 2122 patients with MeVO stroke w­ho underwent MT between September 2017 and July 2023. ENT was defined as filling defects in previously unaffected territories, excluding embolization near the original occlusion, observed on final angiographic runs after retrieval of the primary thrombus. The associations between ENT, procedural variables, and 90-day clinical outcomes were evaluated, including functional independence (modified Rankin Scale (mRS) scores of 0–2), excellent outcomes (mRS 0–1), mortality, and hemorrhagic complications. Results ENT occurred in 2.9% (63/2122) of patients. Longer onset-to-arterial puncture time (adjusted OR 1.03; 95% CI 1.01 to 1.05; P=0.002) and a greater number of passes (adjusted OR 1.15; 95% CI 1.01 to 1.32; P=0.032) were associated with increased ENT risk, while excellent recanalization (thrombolysis in cerebral infarction (TICI) scale score 2c–3) was associated with reduced ENT risk (adjusted OR 0.41; 95% CI 0.23 to 0.72; P=0.002). ENT was not associated with poorer functional independence, mortality, or hemorrhagic complications. Conclusions ENT during MT for MeVO stroke occurs infrequently and does not significantly affect the clinical outcomes. These findings suggest ENT risk should not deter clinicians from performing MT in patients with MeVO. Further prospective studies are needed to validate these results.

13 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MDMotaz Daraghma
Motaz Daraghma
YAYashant Aswani
Yashant Aswani
SJSanchay Jain
Sanchay Jain
Riccardo LaudicellaRiccardo Laudicella
Riccardo Laudicella
AGAli Gholamrezanezhad
Ali Gholamrezanezhad
Ahmad ShariftabriziAhmad Shariftabrizi
Ahmad Shariftabrizi
Paraneoplastic syndromes (PNSs) are pathologic conditions produced by neoplasms not attributable to tumor invasion or metastasis. The clinical manifestations of PNSs can precede the diagnosis; these symptoms may serve as early indicators of underlying malignancy. Standard imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), have limited sensitivity in detecting small or early-stage PNS-associated tumors. FDG PET/CT identifies hypermetabolic lesions suggestive of malignancy and, therefore, facilitates early diagnosis, refined treatment planning, and potentially prolonged patient survival. This review evaluates the diagnostic accuracy, clinical utility, and emerging role of FDG PET/CT in detecting occult malignancies. Syndrome-targeted applications discussed include limbic encephalitis, cerebellar degeneration, Lambert-Eaton myasthenic syndrome, Cushing’s syndrome, hypercalcemia of malignancy, dermatomyositis, and tumor-induced osteomalacia. In addition, the limitations of FDG PET/CT, including false-positive or false-negative findings, are reviewed, while newer PET tracers, like 68Ga-DOTATATE, are also highlighted. Ultimately, FDG PET/CT has transformed clinical decision-making, enabling more timely interventions and improved patient management in the context of PNSs. Future directions in imaging, including PET/MRI and ongoing refinements in tracer design, promise to further enhance diagnostic precision, and therapeutic outcomes are also discussed.